JP2024540863A5 - - Google Patents
Info
- Publication number
- JP2024540863A5 JP2024540863A5 JP2024522065A JP2024522065A JP2024540863A5 JP 2024540863 A5 JP2024540863 A5 JP 2024540863A5 JP 2024522065 A JP2024522065 A JP 2024522065A JP 2024522065 A JP2024522065 A JP 2024522065A JP 2024540863 A5 JP2024540863 A5 JP 2024540863A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- taa
- multispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/123374 | 2021-10-12 | ||
| CN2021123374 | 2021-10-12 | ||
| CNPCT/CN2022/104995 | 2022-07-11 | ||
| CN2022104995 | 2022-07-11 | ||
| PCT/CN2022/124961 WO2023061417A1 (en) | 2021-10-12 | 2022-10-12 | Cd3-targeting t-cell engagers with improved therapeutic index |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540863A JP2024540863A (ja) | 2024-11-06 |
| JP2024540863A5 true JP2024540863A5 (enExample) | 2025-10-22 |
Family
ID=85987305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522065A Pending JP2024540863A (ja) | 2021-10-12 | 2022-10-12 | 改善された治療指数を有するｃｄ３標的化ｔ細胞エンゲージャー |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240417469A1 (enExample) |
| EP (1) | EP4415825A4 (enExample) |
| JP (1) | JP2024540863A (enExample) |
| CN (1) | CN118556083A (enExample) |
| WO (1) | WO2023061417A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122070305A (zh) * | 2023-09-21 | 2026-05-19 | 艾科联生物科技(上海)有限公司 | 多特异性抗体及其用途 |
| WO2025103425A1 (en) * | 2023-11-15 | 2025-05-22 | Concept To Medicine Biotech Co., Ltd. | Multispecific antibodies and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY200973A (en) * | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| TW202010757A (zh) * | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| WO2020023553A1 (en) * | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| JP2022501325A (ja) * | 2018-09-28 | 2022-01-06 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子 |
| CN113166261A (zh) * | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| US12590169B2 (en) * | 2018-10-11 | 2026-03-31 | Inhibrx Biosciences, Inc. | 5T4 single domain antibodies and therapeutic compositions thereof |
| CN110669137B (zh) * | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
| EP4110820A4 (en) * | 2020-02-25 | 2024-03-27 | Gensun Biopharma Inc. | Trispecific t cell engagers |
-
2022
- 2022-10-12 CN CN202280082274.2A patent/CN118556083A/zh active Pending
- 2022-10-12 WO PCT/CN2022/124961 patent/WO2023061417A1/en not_active Ceased
- 2022-10-12 EP EP22880353.2A patent/EP4415825A4/en active Pending
- 2022-10-12 US US18/700,213 patent/US20240417469A1/en active Pending
- 2022-10-12 JP JP2024522065A patent/JP2024540863A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niquille et al. | Biparatopic antibodies: therapeutic applications and prospects | |
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| JP7438958B2 (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| Zhou et al. | Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies | |
| JP2022545660A5 (enExample) | ||
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| Pekar et al. | Biophysical and biochemical characterization of a VHH-based IgG-like bi-and trispecific antibody platform | |
| JP2023537002A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| KR20170085531A (ko) | 항-cldn 키메라 항원 수용체 및 사용 방법 | |
| JP2023524102A5 (enExample) | ||
| JP2024001073A5 (enExample) | ||
| CN114466868A (zh) | 一种双特异性融合蛋白及其应用 | |
| JP2024537321A5 (enExample) | ||
| JP2024515560A5 (enExample) | ||
| CN110072892A (zh) | Mg7，高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 | |
| JP2021512604A5 (enExample) | ||
| WO2023071676A1 (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| JP2023502990A5 (enExample) | ||
| CN113150156A (zh) | 抗tigit抗体及其用途 | |
| Sugiyama et al. | A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity | |
| WO2021092266A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| US20260092116A1 (en) | B7h3/pdl1 bispecific antibody, and pharmaceutical composition comprising same and use thereof | |
| WO2024037628A1 (zh) | 一种双特异性抗体及其应用 |